The product functions as an intelligent layer within the broader Veeva AI suite, focusing on the labor-intensive aspects of pharmacovigilance. By automating the follow-up and intake stages, the company intends to lower operational costs while accelerating response times for biopharma organizations. Marius Mortensen, vice president of product for Falcon, noted that the tool was developed through direct collaboration with global safety specialists and case processors to modernize legacy operations.
Veeva Launches AI-Driven Falcon Safety for Universal Case Management
Veeva Systems is expanding its life sciences portfolio with Falcon Safety, an agentic product designed to automate adverse event intake and case processing. By extending its reach beyond native software to include any E2B-compliant system like Oracle Argus or ArisGlobal LifeSphere, the platform aims to standardize compliance workflows across the industry.
Early adopter availability is scheduled for November 2026. This release marks a shift toward agnostic interoperability, allowing companies to integrate Falcon Safety into existing infrastructure without replacing their current safety databases. Veeva currently serves over 1,500 customers, positioning this AI-native tool as a scalable solution for both emerging biotech firms and large-scale pharmaceutical enterprises.
Comments (0)
No comments yet. Be the first!